Cargando…

White matter lesion location correlates with disability in relapsing multiple sclerosis

BACKGROUND: Lesion location is a prognostic factor of disease progression and disability accrual. OBJECTIVE: To investigate lesion formation in 11 brain regions, assess correlation between lesion location and physical and cognitive disability measures and investigate treatment effects by region. MET...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gaetano, Laura, Magnusson, Baldur, Kindalova, Petya, Tomic, Davorka, Silva, Diego, Altermatt, Anna, Magon, Stefano, Müller-Lenke, Nicole, Radue, Ernst-Wilhelm, Leppert, David, Kappos, Ludwig, Wuerfel, Jens, Häring, Dieter A, Sprenger, Till
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2020
Materias:	Original Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7031799/ https://www.ncbi.nlm.nih.gov/pubmed/32128236 http://dx.doi.org/10.1177/2055217320906844

Ejemplares similares

Association of brain volume loss and long-term disability outcomes in patients with multiple sclerosis treated with teriflunomide
por: Sprenger, Till, et al.
Publicado: (2019)

Inclusion of brain volume loss in a revised measure of ‘no evidence of disease activity’ (NEDA-4) in relapsing–remitting multiple sclerosis
por: Kappos, Ludwig, et al.
Publicado: (2015)

Onset of clinical and MRI efficacy occurs early after fingolimod treatment initiation in relapsing multiple sclerosis
por: Kappos, Ludwig, et al.
Publicado: (2015)

Teriflunomide slows BVL in relapsing MS: A reanalysis of the TEMSO MRI data set using SIENA
por: Radue, Ernst-Wilhelm, et al.
Publicado: (2017)

Subcortical brain segmentation of two dimensional T1-weighted data sets with FMRIB's Integrated Registration and Segmentation Tool (FIRST)
por: Amann, Michael, et al.
Publicado: (2014)

White matter lesion filling improves the accuracy of cortical thickness measurements in multiple sclerosis patients: a longitudinal study
por: Magon, Stefano, et al.
Publicado: (2014)

A comparison of brain magnetic resonance imaging lesions in multiple sclerosis by race with reference to disability progression
por: Nakamura, Yuri, et al.
Publicado: (2018)

Baseline characteristics and effects of fingolimod on cognitive performance in patients with relapsing‐remitting multiple sclerosis
por: Langdon, Dawn W., et al.
Publicado: (2021)

Blood Neurofilament Light in Progressive Multiple Sclerosis: Post Hoc Analysis of 2 Randomized Controlled Trials
por: Leppert, David, et al.
Publicado: (2022)

Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS
por: Kappos, Ludwig, et al.
Publicado: (2015)

Long-term prognostic value of longitudinal measurements of blood neurofilament levels
por: Häring, Dieter A., et al.
Publicado: (2020)

Cerebellar Abnormalities Contribute to Disability Including Cognitive Impairment in Multiple Sclerosis
por: Weier, Katrin, et al.
Publicado: (2014)

Correlation between brain volume loss and clinical and MRI outcomes in multiple sclerosis
por: Radue, Ernst-Wilhelm, et al.
Publicado: (2015)

Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosis
por: Cree, Bruce AC, et al.
Publicado: (2020)

Additive and interaction effects of working memory and motor sequence training on brain functional connectivity
por: Zuber, Priska, et al.
Publicado: (2021)

Longitudinal patterns of cortical thinning in multiple sclerosis
por: Tsagkas, Charidimos, et al.
Publicado: (2020)

Disability improvement as a clinically relevant outcome in clinical trials of relapsing forms of multiple sclerosis
por: Cree, Bruce AC, et al.
Publicado: (2021)

Effects of teriflunomide treatment on cognitive performance and brain volume in patients with relapsing multiple sclerosis: Post hoc analysis of the TEMSO core and extension studies
por: Sprenger, Till, et al.
Publicado: (2022)

Regional Cerebellar Volume Loss Predicts Future Disability in Multiple Sclerosis Patients
por: Parmar, Katrin, et al.
Publicado: (2021)

Blood neurofilament light as a potential endpoint in Phase 2 studies in MS
por: Sormani, Maria Pia, et al.
Publicado: (2019)

Blood neurofilament light chain as a biomarker of MS disease activity and treatment response
por: Kuhle, Jens, et al.
Publicado: (2019)

Longitudinal changes of deep gray matter shape in multiple sclerosis
por: Tsagkas, Charidimos, et al.
Publicado: (2022)

Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis
por: Kuhle, Jens, et al.
Publicado: (2015)

The ACROSS study: Long-term efficacy of fingolimod in patients with relapsing–remitting multiple sclerosis
por: Derfuss, T, et al.
Publicado: (2020)

Central nervous system atrophy predicts future dynamics of disability progression in a real‐world multiple sclerosis cohort
por: Tsagkas, Charidimos, et al.
Publicado: (2021)

Classification of multiple sclerosis based on patterns of CNS regional atrophy covariance
por: Tsagkas, Charidimos, et al.
Publicado: (2021)

Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study
por: Gold, Ralf, et al.
Publicado: (2013)

Voxel-wise and spatial modelling of binary lesion masks: Comparison of methods with a realistic simulation framework
por: Kindalova, Petya, et al.
Publicado: (2021)

Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study
por: Gold, Ralf, et al.
Publicado: (2016)

Learning ability correlates with brain atrophy and disability progression in RRMS
por: Sormani, Maria Pia, et al.
Publicado: (2019)

Addendum to “A white matter lesion-filling approach to improve braintissue volume measurements” [NeuroImage Clin. vol. 6, 2014, pages 86–92]
por: Magon, Stefano, et al.
Publicado: (2014)

Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis
por: Giovannoni, Gavin, et al.
Publicado: (2013)

A comparative assessment of myelin-sensitive measures in multiple sclerosis patients and healthy subjects
por: Rahmanzadeh, Reza, et al.
Publicado: (2022)

Long-term safety and efficacy of daclizumab beta in relapsing–remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study
por: Gold, Ralf, et al.
Publicado: (2020)

Neurofilament light chain serum levels correlate with 10‐year MRI outcomes in multiple sclerosis
por: Chitnis, Tanuja, et al.
Publicado: (2018)

Two-year results from a phase 2 extension study of oral amiselimod in relapsing multiple sclerosis
por: Kappos, Ludwig, et al.
Publicado: (2017)

Spatial distribution and cognitive impact of cerebrovascular risk-related white matter hyperintensities
por: Veldsman, Michele, et al.
Publicado: (2020)

α4-integrin receptor desaturation and disease activity return after natalizumab cessation
por: Derfuss, Tobias, et al.
Publicado: (2017)

Ocrelizumab reduces thalamic volume loss in patients with RMS and PPMS
por: Arnold, Douglas L, et al.
Publicado: (2022)

No Evidence of Disease Activity: Indirect Comparisons of Oral Therapies for the Treatment of Relapsing–Remitting Multiple Sclerosis
por: Nixon, Richard, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_grh4asflr8cu4bohttd1ntb2at